The cellular immune response to HIV has been shown to be robust and continues throughout the natural history of the infection. The capacity for CTL to diminish viral load is substantial, however, sequence variation of HIV limits the effectiveness of the CTL response. Combination pharmacologic therapy against HIV infection known as HAART, has dramatically decreased viral load in many AIDS patients. Despite this control of viral replication, patients who are HAART-responsive for a period of two years or greater, still harbor infectious virus that may, under the appropriate circumstance, become active in replication and cause serious health consequences. The purpose of these studies is to develop immunization strategies in murine models based on immunodominant CTL epitopes from HIV proteins in combination with T-help (HTL) epitopes as part of lipidated peptides. Epitopes will be chosen from sequence-conserved regions of immunogenic HIV proteins. These epitopes will be made into combination vaccines consisting of covalently attached and lipidated HTL+CTL epitopes. The initial approach is to determine the most efficacious means using lipidated vaccines to immunize transgenic mice expressing human HLA Class I and Class II MHC antigens. Mucosal and subcutaneous routes of immunization will be explored. The success of immunization strategies will be evaluated by in vitro methods including the recognition of human antigen presenting cells (APC) which will be infected with different isolates of HIV. The choice of CTL epitope will be made using the criteria that the recognition should be restricted by common HLA Class I alleles. One of the main goals of the proposal and the Innovation Grant Program is to evaluate means to propagate the CTL response using strong T-help (HTL) epitopes. The applicants will evaluate a series of HTL epitopes in combination with selected CTL epitopes using immunization strategies detailed in the proposal. The efficacy of the immune strategies will be examined further using a mouse model of HIV infection referred to as the huPBL-SCID mouse. Immunodeficient mice will be repopulated with human PBL of known HLA type and infected with various isolates of HIV. Vaccine stimulated CTL obtained from transgenic mice will be infused in the previously HIV infected huPBL SCID mice to evaluate their potential for recognition/lysis of infected cells and reduction of viral load. The vaccine strategy that results in the most successful reduction in viral load should be considered in terms of future human immunization clinical protocols for patients on HAART during the time when viral replication is suppressed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI044313-02
Application #
2887887
Study Section
Special Emphasis Panel (ZAI1-PRJ-A (S1))
Program Officer
Bende, Steve M
Project Start
1998-09-30
Project End
2002-08-31
Budget Start
1999-09-01
Budget End
2002-08-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Villacres, Maria C; Literat, Oana; Degiacomo, Marina et al. (2005) Reduced type 1 and type 2 cytokines in antiviral memory T helper function among women coinfected with HIV and HCV. J Clin Immunol 25:134-41
Gibson, Laura; Piccinini, Giampiero; Lilleri, Daniele et al. (2004) Human cytomegalovirus proteins pp65 and immediate early protein 1 are common targets for CD8+ T cell responses in children with congenital or postnatal human cytomegalovirus infection. J Immunol 172:2256-64
Villacres, Maria C; Longmate, Jeff; Auge, Catherine et al. (2004) Predominant type 1 CMV-specific memory T-helper response in humans: evidence for gender differences in cytokine secretion. Hum Immunol 65:476-85
Lacey, Simon F; Diamond, Don J; Zaia, John A (2004) Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant 10:433-47
Lacey, Simon F; Villacres, Maria C; La Rosa, Corinna et al. (2003) Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles. Hum Immunol 64:440-52
Daftarian, Pirouz; Ali, Saima; Sharan, Rahul et al. (2003) Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J Immunol 171:4028-39
Villacres, Maria C; Lacey, Simon F; Auge, Catherine et al. (2003) Relevance of peptide avidity to the T cell receptor for cytomegalovirus-specific ex vivo CD8 T cell cytotoxicity. J Infect Dis 188:908-18
Espenschied, Jonathan; Lamont, Jeffrey; Longmate, Jeff et al. (2003) CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-7
La Rosa, Corinna; Wang, Zhongde; Brewer, John C et al. (2002) Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100:3681-9
Gallez-Hawkins, G; Lomeli, N A; L Li, X et al. (2002) Kinase-deficient CMVpp65 triggers a CMVpp65 specific T-cell immune response in HLA-A*0201.Kb transgenic mice after DNA immunization. Scand J Immunol 55:592-8

Showing the most recent 10 out of 11 publications